相关实验视频

Updated: May 16, 2025

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

赫斯佩里丁对脂质概况,炎症和试验糖尿病中的亡的影响

Kenan Yıldızhan¹, Mehmet Hafit Bayir², Zübeyir Huyut³

¹Department of Biophysics, Faculty of Medicine, an Yuzuncu Yil University, Van, Türkiye. kenanyldzhan@gmail.com.

Doklady. Biochemistry and biophysics

|April 11, 2025

概括

黑斯佩里丁 (HESP) 有效地防止糖尿病引起的肝损伤. 在类水果中发现的这种天然化合物有助于使肝脏酶,脂质正常化,并减少糖尿病患者的炎症和亡.

科学领域:

生物化学生化学
药理学药理学是指药理学的学科.
肝病学肝病学是一种肝病学.

背景情况:

糖尿病是一种重要的全球健康问题,经常导致肝损伤等并发症.
类水果中的黄类化合物,如类水果中的素 (HESP),显示出有前途的治疗性质,包括抗氧化和抗炎作用.
了解HESP对糖尿病引起的肝损伤的保护机制对于开发新疗法至关重要.

研究的目的:

在大鼠模型中研究素 (HESP) 对链毒素 (STZ) 诱导的肝损伤的保护作用.
评估HESP对糖尿病肝损伤中的关键生化标志物,炎症性细胞因子和亡指标的影响.

主要方法:

这项研究使用了四个实验组的老鼠模型:对照组,HESP治疗组,STZ诱导的糖尿病患者和STZ + HESP治疗组.
生物化学参数 (AST,ALT,LDH,LDL,甘油三,总胆固醇) 和TNF-α,IL-1β和caspase-3的肝组织表达被测量.
进行了统计分析,以比较两组之间的差异 (p < 0.05).

主要成果:

与对照组相比,毒素 (STZ) 显著增加了血清肝酶,脂质样本和TNF-α,IL-1β和caspase-3的肝脏表达.
在STZ诱导的糖尿病大鼠中,Hesperidin (HESP) 剂量显著降低了这些升高的标志物.
治疗HESP使脂质样本正常化,减少了促炎性细胞因子,并降低了肝脏中亡的指标.

结论:

黑斯佩里丁 (HESP) 显示出对糖尿病引起的肝损伤有显著的保护作用.
通过减少炎症,改善脂质代谢和抑制亡,HESP疗法可以改善肝损伤.
这些发现表明,HESP作为糖尿病肝脏并发症的治疗方法具有治疗潜力.

关键词:

灭症 (apoptosis) 是一种死亡的过程.糖尿病糖尿病患者糖尿病患者这就是hesperidin.这是一种炎症炎症炎症炎症.肝脏受损肝脏受损肝脏受损

更多相关视频

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...